News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EMD Serono, Inc. (Rockland) to Present New Data on Multiple Sclerosis at the American Academy of Neurology’s 64th Annual Meeting


4/20/2012 10:14:10 AM

ROCKLAND, Mass.--(BUSINESS WIRE)--EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company’s multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology’s 64th Annual Meeting, taking place from April 21 to 28, in New Orleans, Louisiana. The data presented will focus on Rebif® (interferon beta-1a), an established therapy for relapsing forms of MS, and ONO-4641 (S1P receptor agonist), an investigational oral drug in Phase II for the treatment of relapsing-remitting MS, for which Merck KGaA signed a collaboration agreement with Ono Pharmaceuticals in October 2011.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES